Holen Sie sich die Stockscreener-App
9.82
0.91%
-0.09
Schlusskurs vom Vortag:
$9.91
Offen:
$10
24-Stunden-Volumen:
494.93K
Relative Volume:
0.18
Marktkapitalisierung:
$1.48B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-738.82M
KGV:
-1.4109
EPS:
-6.9602
Netto-Cashflow:
$-610.15M
1W Leistung:
-1.01%
1M Leistung:
-13.56%
6M Leistung:
-29.50%
1J Leistung:
-65.20%
1-Tages-Spanne:
$9.82
$10.37
1-Wochen-Bereich:
$9.25
$12.10
52-Wochen-Spanne:
$7.48
$31.18
Biohaven Ltd Stock (BHVN) Company Profile
Firmenname
Biohaven Ltd
Sektor
Branche
Telefon
203-404-0410
Adresse
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
9.83 | 1.49B | 0 | -738.82M | -610.15M | -6.9602 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.37 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.22 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.32 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.61 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.49 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-06 | Eingeleitet | Goldman | Buy |
| 2026-01-21 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | Herabstufung | UBS | Buy → Neutral |
| 2025-11-06 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-03 | Eingeleitet | Raymond James | Strong Buy |
| 2025-05-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-09-16 | Eingeleitet | Jefferies | Buy |
| 2024-09-04 | Eingeleitet | Bernstein | Outperform |
| 2024-07-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-02-06 | Eingeleitet | UBS | Buy |
| 2023-12-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-12-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-01-24 | Eingeleitet | SVB Securities | Outperform |
| 2023-01-04 | Eingeleitet | JP Morgan | Overweight |
| 2022-12-02 | Eingeleitet | BTIG Research | Buy |
| 2022-10-26 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-05-11 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Herabstufung | UBS | Buy → Neutral |
| 2021-08-03 | Bestätigt | Canaccord Genuity | Buy |
| 2021-03-11 | Eingeleitet | UBS | Buy |
| 2020-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-17 | Eingeleitet | Cowen | Outperform |
| 2020-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Outperform |
| 2019-06-25 | Bestätigt | Canaccord Genuity | Buy |
| 2019-05-06 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Bestätigt | Needham | Buy |
| 2018-07-03 | Bestätigt | Needham | Buy |
| 2018-07-02 | Bestätigt | Needham | Buy |
| 2018-04-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Bestätigt | Canaccord Genuity | Buy |
| 2017-12-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-10-03 | Bestätigt | Needham | Buy |
Alle ansehen
Biohaven Ltd Aktie (BHVN) Neueste Nachrichten
TD Cowen Boosts Biohaven (NYSE:BHVN) Price Target to $30.00 - MarketBeat
Assessing Biohaven (BHVN) Valuation After Pipeline Optimism And Supportive Sector Sentiment - simplywall.st
Why Biohaven (BHVN) Is Down 13.5% After Narrower Losses And A New Share Shelf Registration - simplywall.st
Raymond James Maintains Strong Buy on Biohaven Ltd. (BHVN) March 2026 - Meyka
Raymond James reiterates Strong Buy on Biohaven stock after competitor data - Investing.com Australia
Biohaven Reports Q4 EPS Beat Expectations, Plans Stock Issuance - Intellectia AI
Biohaven (NYSE:BHVN) Shares Gap UpTime to Buy? - MarketBeat
Biohaven Ltd stock whipsaws after FDA exit revives rare-disease bets - Bez Kabli
What's Going On With Biohaven Stock On Monday? - Benzinga
Breakout Watch: Can Biohaven Ltd stock outperform in a bear marketJuly 2025 PostEarnings & Risk Managed Trade Strategies - baoquankhu1.vn
Death Cross: Is Biohaven Ltd a stock for growth or value investors2025 Winners & Losers & Reliable Trade Execution Plans - baoquankhu1.vn
Technical Reactions to BHVN Trends in Macro Strategies - Stock Traders Daily
TD Asset Management Inc Cuts Stake in Biohaven Ltd. $BHVN - MarketBeat
Biohaven stock price target lowered to $10 by H.C. Wainwright - Investing.com South Africa
Biohaven (NYSE:BHVN) Given New $10.00 Price Target at HC Wainwright - MarketBeat
BHVN Earnings History & Surprises | EPS & Revenue Results | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
BHVN: HC Wainwright & Co. Lowers Price Target While Maintaining - GuruFocus
Assessing Biohaven (BHVN) Valuation After Recent Share Price Volatility - simplywall.st
Biohaven Reshapes Pipeline And Funding As Late Stage Trials Approach - Yahoo Finance
Biohaven (BHVN) VP and CAO awarded 50,000 stock options with 4-year vesting - Stock Titan
Biohaven (BHVN) CFO awarded 175,000 stock options in Form 4 filing - Stock Titan
Biohaven Ltd. (BHVN) SVP awarded 175,000 stock options with 4-year vesting - Stock Titan
Biohaven (BHVN) Chief Scientific Officer awarded 175,000 stock options - Stock Titan
Biohaven (BHVN) CEO Vlad Coric granted 550,000 stock options - Stock Titan
Key facts: Biohaven posts $738.8M loss; opakalim shows promise in study; analysts give 'buy' rating - TradingView
Biohaven (NYSE:BHVN) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says - MarketBeat
Piper Sandler reiterates Biohaven stock rating on 2026 catalysts By Investing.com - Investing.com Canada
Piper Sandler reiterates Biohaven stock rating on 2026 catalysts - Investing.com Nigeria
Biohaven Ltd. (BHVN) Stock Analysis: Exploring a 77% Potential Upside with Strong Buy Ratings - DirectorsTalk Interviews
RBC Raises Price Target on Biohaven to $23 From $22, Keeps Outperform, Speculative Risk - marketscreener.com
JPMorgan Chase & Co. Reduces Stake in Biohaven Ltd. $BHVN - MarketBeat
Biohaven Ltd. Common Shares (NY: BHVN - The Chronicle-Journal
Biohaven Ltd reports results for the quarter ended September 30Earnings Summary - TradingView
Biohaven (NYSE:BHVN) Announces Earnings Results - MarketBeat
Biohaven (NYSE: BHVN) refocuses pipeline after key trial and FDA setbacks - Stock Titan
Biohaven 10-K: $0 Revenue, $(0.74)B Net Loss; Cash ~$319M - TradingView
Earnings Flash (BHVN) Biohaven Ltd. Posts Q4 Adjusted Loss $0.90 per Share, vs. FactSet Est of $-0.87 - marketscreener.com
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results - PR Newswire
How US$600 Million Non-Dilutive Funding and R&D Cuts Will Impact Biohaven (BHVN) Investors - simplywall.st
Biohaven Ltd. (BHVN): A Bull Case Theory - Yahoo Finance
BHVN Should I Buy - Intellectia AI
Assessing Biohaven (BHVN) Valuation After A Sharp One Year Decline And Recent Three Month Rebound - simplywall.st
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biohaven Ltd. (BHVN) Stock Analysis: Navigating a Potential 80% Upside in the Biotechnology Sector - DirectorsTalk Interviews
Trading the Move, Not the Narrative: (BHVN) Edition - Stock Traders Daily
Biohaven (BHVN) Projected to Post Earnings on Monday - MarketBeat
Is Biohaven Ltd. stock a good pick for beginnersWeekly Trade Report & Expert Curated Trade Setup Alerts - mfd.ru
Biohaven Ltd. (BHVN) Stock Analysis: A Biotech Challenger With An 84% Potential Upside - DirectorsTalk Interviews
Raymond James Begins Coverage of Biohaven with Strong Buy Rating and Sets Price Target at $75 - Intellectia AI
What catalysts could drive Biohaven Ltd. stock higherTrade Exit Summary & Real-Time Volume Analysis - mfd.ru
Biohaven CEO Vlad Coric to Present at J.P. Morgan Healthcare Conference on January 12, 2026 - Intellectia AI
Finanzdaten der Biohaven Ltd-Aktie (BHVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):